and that $3 billion in revenue would roughly equate to a market value of $15 Billion or more, as biotechs typically trade at 5-6X revenue on a market value basis. Given that our current market cap is about 300 million, that would be a return of 50X from here, or about $20 / share.

Or, said another way, let's get that damn BLA done!!!